Fatty acid-binding protein-4 as a biomarker predicting acromegaly-associated diabetes mellitus

Sema HEPŞEN*, Pınar AKHANLI, Hakan DÜGER, Murat ÇALAPKULU, Bekir UÇAN, Muhammed Erkam SENCAR, Davut SAKIZ, İlkür ÖZTÜRK ÜNSAL, Seyit Murat BAYRAM, Mustafa ÖZBEK, Erman ÇAKAL
Department of Endocrinology and Metabolism, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

* Correspondence: semahepsen@gmail.com

1. Introduction
Acromegaly develops as a result of excessive growth hormone (GH) and insulin-like growth factor-1 (IGF-1) release and is caused mostly by a pituitary adenoma. The estimated incidence of this rare condition was reported as 0.2–1.1 cases/100000 people/year [1]. Diabetes mellitus (DM), impaired glucose metabolism, insulin resistance, hypertension, and cardiovascular diseases are common in acromegaly and contribute to increased risk of mortality [2,3]. Impaired glucose metabolism is one of the most common metabolic morbidities in acromegaly, and the reported prevalence ranges from 15% to 50% depending on the genetic and ethnic factors of the patients [2]. DM frequency in acromegaly has been indicated in a wide range of 16% to 56% in various studies from different populations [4–6].

Despite the impacts of genetic, familial, and environmental risk factors on type 2 DM occurrence, it is known that DM in acromegaly develops as a result of the effects of GH and IGF-1 excess on the pancreatic β-cell function, insulin sensitivity, and gluconeogenesis [7]. Recent studies have revealed that altered adipokine variety and quantity in adipose tissue might contribute to the pathogenesis of insulin resistance and DM in patients with acromegaly [8].

Fatty acid-binding protein-4 (FABP-4) is a novel adipokine, which is expressed in adipocytes and plays a part in the initiative mechanism of insulin resistance and type 2 DM via suppressing PPAR gamma [9]. FABP-4 induced PPAR gamma inhibition particularly acts as a role in lipid-mediated inflammation and oxidation processes [9]. With the initiation of this inflammatory process, glycolysis and glucose oxidation begin to be inhibited and the glucose uptake of peripheral tissues, mainly the liver and muscles, reduces [9]. Thus, increased FABP-4 leads to the development of insulin resistance as a consequence of defective insulin secretion. Previous studies have established that FABP-4 was linked to type 2 DM, gestational DM, and metabolic syndrome [10–12]. Although adequate data in the linkage between FABP-4...
level and type 2 DM have been presented in the literature, as far as we know, the association between FABP-4 and DM in acromegaly was not investigated before.

Depending on the hypothesis that FABP-4 was closely relevant to glucose metabolism impairment, we aimed to evaluate FABP-4 levels in patients with acromegaly, especially patients with acromegaly-associated DM.

2. Material and methods

2.1. Study design
This study was designed as a case-control study. The Ethics Committee of our institute approved this study regarding the principles of the Helsinki Declaration (Clinical Research Ethics Committee University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Approval number: 71/08). Written informed consent was taken before being participated in the study.

2.2. Patients and laboratory tests

Between December 2017 and December 2019, a total of 28 patients were diagnosed with acromegaly in the endocrinology and metabolism department. Acromegaly diagnosis was based on the Endocrine Society Clinical Practice Guideline [13]. Serum IGF-1 level was measured in patients who had typical acromegaly physical features or had acromegaly associated conditions such as type 2 DM, hypertension, and sleep apnea syndrome in the absence of typical acral and facial stigmata. Anthropometric and laboratory data of the patients were examined at the time of diagnosis, before being undergone a pituitary surgery or being started medical treatment with somatostatin analogs.

The control group was composed of 57 randomly selected healthy subjects who were admitted to our hospital for routine controls and agreed to participate in our study.

Foreknown comorbidities of the patients such as hypertension, DM, and atherosclerotic cardiovascular diseases were questioned. DM of the patients with acromegaly was categorized as newly diagnosed or previously known. Diabetic patients were also questioned for their family history of DM. DM and prediabetes diagnosis criteria were based on the American Diabetes Association (ADA) guidelines. DM and prediabetes diagnosis was based on the Endocrine Society Clinical Practice Guideline [13]. Serum IGF-1 level was measured in patients who had typical acromegaly physical features or had acromegaly associated conditions such as type 2 DM, hypertension, and sleep apnea syndrome in the absence of typical acral and facial stigmata. Anthropometric and laboratory data of the patients were examined at the time of diagnosis, before being undergone a pituitary surgery or being started medical treatment with somatostatin analogs.

The control group was composed of 57 randomly selected healthy subjects who were admitted to our hospital for routine controls and agreed to participate in our study.

Serum samples for the FABP-4 analysis were reserved for an 8:00 and 10:00 am after at least 8 h of overnight fasting. Serum samples for the FABP-4 analysis were reserved for 2 h at room temperature and then centrifuged for 20 min at approximately 1000×g. All serum samples were stored at −80 °C until the day of analysis. A sandwich enzyme immunoassay kit was used to determine in vitro quantitative measurement of FABP-4 (Cloud-Clone Corp, Houston, TX, USA). FPG was determined through the enzymatic UV test (Beckman Coulter AU, USA). HbA1c level was determined by the ion-exchange high-performance liquid chromatography (HPLC) method (Tosoh Bioscience, G8, USA). Serum lipid parameters were examined using the enzymatic colorimetric method (Beckman Coulter AU, USA). Thyroid-stimulating hormone (TSH), insulin, GH, and IGF-1 levels were analyzed via the chemiluminescence immunoassay method (Beckman Coulter, Access 2, USA). HOMA-IR was calculated according to the following formula: FPG (mg/dL) x fasting insulin (mU/ml)/405. Normal ranges of GH and IGF-1 were as follows: 0.05–8 ng/mL, 42–214 ng/mL, respectively.

Echocardiographic examination was performed using a standard ultrasound system (Philips EPIQ 5, Philips Healthcare, USA). Left ventricle ejection fraction (EF) was evaluated based on the modified biplane Simpson’s method. Left ventricular hypertrophy (LVH) was defined as an increase in the size of myocardial fibers of the left ventricle [17].

2.3. Statistical analysis
Statistical analyses were performed using the SPSS software version 21 (Chicago, IL). The variables were investigated by means of visual (histograms, probability plots) and analytic methods (Kolmogorov-Smirnov/Shapiro–Wilk’s test) to determine whether they are normally distributed or not. While the Student’s t-test was used to compare age, waist circumference, creatinine, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels, the Mann–Whitney U test was performed to compare sex, BMI, hip circumference, systolic and diastolic blood pressure, HOMA-IR, FPG, HbA1c, GH, IGF-1, TSH, ALT, and triglyceride levels. Descriptive analyses were presented using means and standard deviations for normally distributed variables, whereas medians and interquartile ranges (IQR) between 25 and 75 percentiles
for nonnormally distributed variables. A p-value less than 0.05 was considered to show a statistically significant difference. The Kruskal-Wallis tests were conducted to compare FABP-4 levels and other laboratory parameters among the groups, which were composed according to their glucose metabolism and insulin resistance status. The Mann–Whitney U test was performed to examine the significance of pairwise differences using Bonferroni correction to adjust for multiple comparisons. Overall, a 5% type-1 error level was used to infer statistical significance. While investigating the associations between FABP-4 level and other variables, correlation coefficients and their significance were calculated using the Spearman test. A logistic regression analysis was used to identify the independent predictors of DM in acromegaly. Hosmer–Lemeshow goodness of fit statistics was used to assess model fit. A 5% type-I error level was used to infer statistical significance.

3. Results
Twenty-eight patients newly diagnosed with acromegaly and 57 controls were included in the study. The age and sex distribution of the controls were similar to the patients with acromegaly ($p > 0.05$). The patients with acromegaly had higher BMI and waist circumference than controls ($p = 0.014$, $p = 0.02$ respectively). All of the patients with acromegaly had a pituitary adenoma. Five (17.8%) patients had a microadenoma, while 23 (82.2%) had a macroadenoma. 26 (92.8%) patients underwent a transnasal transphenoidal pituitary surgery, and 2 (7.2%) patients were started on somatostatin analog treatment as the first-line therapy. A total of 46.4% of patients with acromegaly had hypertension. Systolic and diastolic blood pressure values were higher in the patients with acromegaly than in the control group ($p = 0.001$ and $p < 0.001$, respectively). Nine of 28 patients with acromegaly (32.1%) had DM and 9 of 28 (32.1%) had prediabetes. Only one patient with acromegaly had a family history of DM. While 5 of 9 diabetic patients were diagnosed with DM and acromegaly concurrently, 4 patients had a previously diagnosed DM. The initial treatment was a pituitary surgery for all patients with acromegaly with DM and prediabetes, and glucose metabolism was improved in all of these patients after the surgery. Five of 28 patients with acromegaly (17.8%) had insulin resistance. FPG, HbA1c levels, HOMA-IR, GH, and IGF-1 were higher in the patients with acromegaly than that of controls ($p < 0.0001$ for each). Baseline characteristics and laboratory test results belonging to the groups are presented in Table 1.

The difference in FABP-4 levels between all patients with acromegaly and the control group was not statistically significant ($p = 0.286$). A statistically significant difference was observed in FABP-4 levels among the groups when compared the patients with acromegaly having DM and the controls, with acromegaly having DM and prediabetes, with acromegaly having DM and NGT, respectively ($p = 0.014$, $p = 0.004$, $p = 0.001$) (Figure). Despite the difference was not statistically significant, the patients with acromegaly having DM had higher levels of GH compared to the patients with acromegaly having prediabetes and NGT ($p = 0.077$, $p = 133$, respectively). Baseline data, laboratory parameters, and FABP-4 levels of the groups are presented in Table 2.

No difference was observed in FABP-4 levels compared to the patients with and without insulin resistance ($p = 0.380$), obesity ($p = 0.223$), hypertension ($p = 0.995$), and LVH ($p = 0.553$).

We established that the FABP-4 is positively correlated to FPG, HbA1c, and GH levels in the acromegaly group ($r = 0.548; p = 0.003, r = 0.478; p = 0.012, r = 0.418; p = 0.027$, respectively). However, any association is not determined between FABP4 levels and age, sex, BMI, FPG, HbA1c, GH, and IGF-1 in the whole study group including both patients and controls. Logistic regression analysis was calculated to detect independent predictors of DM in acromegaly based on the variables, including age, sex, FABP-4, IGF-1, and GH levels and was presented in Table 3. Logistic regression analysis suggested that the FABP-4 level is an independent predictor of DM but not the other variables ($\beta = 7.382, OR = 38.96, 95\% CI: 1.52-5.76, p = 0.018$).

4. Discussion
The results of the present study demonstrated that FABP-4 levels were higher in the patients with acromegaly having DM compared to the patients without DM and the controls. Logistic regression analysis also suggested that the FABP-4 level is an independent predictor of DM in acromegaly but not age, sex, IGF-1, and GH.

Patients with acromegaly have a higher risk of glucose metabolism disorders compared to the general population [5]. While DM prevalence in the patients with acromegaly varies in the range of 16% to 56% among different study populations, the prevalence of impaired fasting glucose and glucose tolerance have been reported as 8.9% to 19% and 15% to 31.6%, respectively [5,6,18]. Similar to the literature, the frequencies were found out 32.1% for DM and 32.1% for prediabetes in the present study.

GH physiologically affects glucose metabolism and leads to hepatic gluconeogenesis, lipolysis, and glycogenolysis. Increased glucose and free fatty acid production induce insulin resistance in the liver and peripheral tissues [19]. Besides the direct effects of GH contrary to insulin action, GH conduces to improve insulin activity via stimulating IGF-1 [7]. However, the insulin agonistic effect of IGF-1 is inadequate to overcome the direct impact of GH on
glucose metabolism. Impaired glucose metabolism and DM develop as a result of decreased insulin sensitivity and secretion [20].

Adipose tissue, one of the targets of GH excess, plays a significant role in glucose metabolism impairment via lipolytic activity [7]. Previous studies have established that GH increases adipose tissue hormone-sensitive lipase activity and leads to FFA release to the peripheral tissues [7]. This was assumed that adipose tissue dysfunction is more important than the amount of the accumulated

| Demographic and anthropometric data | Patients with acromegaly | Controls | p value |
|------------------------------------|--------------------------|----------|---------|
| Number, n                          | 28                       | 57       |         |
| Age, years                         | 48.2 ± 8.8               | 50.3 ± 10.3 | .319   |
| Female, n (%)                      | 18 (64.3)                | 40 (70.2) | .586   |
| BMI, kg/m²                         | 30.4 (27.6–35.6)         | 28.4 (25–31.8) | .014   |
| Waist circumference, cm            | 98.8 ± 15.3              | 89.3 ± 9.7 | .02    |
| Hip circumference, cm              | 103 (100–120)            | 105 (100–110) | .446  |
| Systolic BP, mm/Hg                 | 120 (120–130)            | 120 (110–120) | .001  |
| Diastolic BP, mm/Hg                | 75 (70–80)               | 70 (60–70) | <.0001 |
| Hypertension, n (%)                | 13 (46.4)                | 0 (0)    | -      |
| Diabetes mellitus, n (%)           | 9 (32.1)                 | 0 (0)    | -      |
| Prediabetes, n (%)                 | 9 (32.1)                 | 0 (0)    | -      |
| Insulin resistance, n (%)          | 5 (17.8)                 | 0 (0)    | -      |
| Obesity, n (%)                     | 15 (53.6)                | 21 (36.8) | .145   |
| LVH, n (%)                         | 8 (28.7)                 | 0 (0)    | .014   |
| EF, %                              | 65 (60–65)               | 65 (60–65) | .888   |

| Laboratory test results            | Patients with acromegaly | Controls | p value |
|------------------------------------|--------------------------|----------|---------|
| FPG, mg/dL                         | 103 (91–138)             | 83 (80–90) | <.0001 |
| HbA1c, %                           | 6.1 (5.7–7)              | 5.6 (5.4–5.7) | <.0001 |
| HOMA–IR                            | 3.7 (1.9–6.4)            | 1.15 (0.9–1.6) | <.0001 |
| Total cholesterol, mg/dl           | 187 ± 19                 | 188 ± 42 | .889    |
| Triglyceride, mg/dl                | 128 (109–189)            | 99 (68–138) | .005   |
| HDL-C, mg/dL                       | 43 ± 8                   | 50 ±10  | .002    |
| LDL-C, mg/dL                       | 129 ± 19                 | 132 ± 35 | .669    |
| Creatinine, mg/dL                  | 0.79 ± 0.2               | 0.83 ± 0.8 | .076   |
| ALT, mg/dL                         | 15 (14–18)               | 18 (15–23) | .088   |
| TSH, µIU/mL                        | 1 (0.6–1.8)              | 1.3 (1–2) | .084    |
| IGF-1, ng/mL                       | 536 (453–629)            | 169 (133–194) | <.0001 |
| GH, ng/mL                          | 10.2 (3.4–35)            | 1.9 (1.45–2.3) | <.0001 |
| FABP-4, ng/mL                      | 1.52 (1.42–1.81)         | 1.61 (1.49–1.87) | .286   |

Categorical data were demonstrated with numbers and percentages (%). Normally distributed variables were presented as means (standard deviations) and nonnormally distributed variables were presented as medians (interquartile range: 25–75).  

**Abbreviations**: BMI: body mass index, BP: blood pressure, LVH: left ventricle hypertrophy, EF: ejection fraction, FPG: fasting plasma glucose, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, ALT: alanine aminotransferase, TSH: thyroid-stimulating hormone, IGF-1: insulin-like growth factor-1, GH: growth hormone, FABP-4: fatty acid-binding protein 4.
visceral fat in the pathogenesis of insulin resistance and DM in acromegaly [19]. Furthermore, the adipose tissue dysfunction changes the variety and quantity of adipokines and a change in adipokine distribution causes a more inflamed fat that is suspected in insulin resistance and DM [8]. These novel studies bring to mind that the occurrence of DM in acromegaly may not be solely mediated with GH.

The FABP-4 is a member of the calycin protein superfamily and is expressed in adipocytes and macrophages [9]. FABP-4 expression particularly enhances

---

**Table 2.** The comparisons of baseline characteristics and laboratory parameters among acromegaly groups in terms of their glucose metabolism statuses and controls

|                        | Acromegaly with DM | Acromegaly with prediabetes | Acromegaly with NGT | Controls | p value DM vs controls | p value DM vs prediabetes | p value DM vs NGT |
|------------------------|--------------------|-----------------------------|---------------------|----------|------------------------|--------------------------|-------------------|
| Number, n (%)          | 9 (32.1)           | 9 (32.1)                    | 10 (35.8)           | 57 (100) | 0.385                  | 1.00                     | 0.963             |
| Female/male             | 5/4                | 5/4                         | 8/2                 | 40/17    |                        |                          |                   |
| BMI, kg/m²              | 29.2 (28–31.7)     | 36.8 (28–42)                | 30.5 (25.6–33.6)    | 28.4      | 0.318                  | 0.149                    | 0.963             |
| FABP-4, ng/mL           | 2 (1.71–2.23)      | 1.47 (1.42–1.55)            | 1.47 (1.34–1.58)    | 1.6 (1.49–1.87) | 0.014 | 0.004 | 0.001 |
| FPG, mg/dL             | 175 (130–189)      | 104 (99–106)                | 90 (82–95)          | 83 (80–90) | <0.001 | <0.001 | <0.001 |
| HbA1c, %               | 9.8 (7.5–12.4)     | 6.1 (6.6–6.3)               | 5.6 (5.6–5.7)       | 5.6 (5.4–5.7) | <0.001 | <0.001 | <0.001 |
| IGF-1, ng/mL           | 507 (421–632)      | 545 (442–787)               | 536 (446–602)       | 169 (133–194) | <0.001 | 0.077 | 0.133 |
| GH, ng/mL              | 21 (9.4–40)        | 8 (3–18.3)                  | 5.5 (1.7–24.5)      | 1.9 (1.45–2.3) | <0.001 | 0.436 | 0.842 |

Nonnormally distributed variables were presented as medians (interquartile range: 25–75).

**Abbreviations:** FABP-4: fatty acid-binding protein 4, DM: diabetes mellitus, NGT: normal glucose tolerance, BMI: body mass index, FPG: fasting plasma glucose, IGF-1: insulin-like growth factor-1, GH: growth hormone.
FABP-4 acts a crucial role in glucose and lipid homeostasis through mediating inflammation and oxidation. The FABP-4 affects glucose metabolism via negatively regulating PPAR gamma activity, which promotes adipocyte differentiation, proliferation, and insulin sensitivity of adipocytes [21,22]. With the activation of this inflammatory process, the inhibition of glucose oxidation and glycolysis begins, and glucose uptake of peripheral tissues such as the liver and muscles decreases [9]. FABP-4 also contributes to insulin resistance by accumulating short-chain-free fatty acids. Previous studies have established that FABP-4 is associated with type 2 DM, gestational DM, cardiovascular diseases, obesity, and metabolic syndrome [23–25]. A 10-year study including the Chinese population has demonstrated that the FABP-4 level is a predictor of DM development [26]. Another study including the U.S. male participants have determined that the FABP-4 level is associated with the increased risk of DM [12]. In this study, there was no difference in FABP-4 levels among the groups with and without obesity, hypertension, and LVH. According to the results of the present study, the FABP-4 level was found to be higher in patients with acromegaly and DM. Only one patient had a family history of DM in our diabetic acromegaly group. DM was diagnosed concurrently with acromegaly in most of the patients. Glucose metabolism of all patients with DM and prediabetes was improved after the surgery as well. All these findings taken together indicate that the diagnosis of DM of our patients with acromegaly was related to acromegaly rather than concomitant type 2 DM to acromegaly. This is noteworthy to point that the correlation analysis of this study showed a linear association between FABP-4 level and HbA1c in the acromegaly group. The patients with acromegaly having DM have also a higher HbA1c than the other 3 groups. With respect to these results, it can be commented that a higher FABP-4 level may indicate poorly controlled DM. However, there was no difference between our patients with and without insulin resistance. The small sample size belonging to subgroups may be the explanation for this discrepancy.

This was also shown that GH modulates the expression of gene-related adipocyte differentiation and inhibits the expression of various molecules including adiponectin and PPAR gamma [27]. In the present study, the patients with acromegaly having DM had higher GH levels compared to the patients with acromegaly having prediabetes and NGT, and FABP-4 was found positively correlated to GH. It may be hypothesized that GH may also be mediating FABP-4 expression because they both induce PPAR gamma inhibition.

Various studies have indicated that higher levels of IGF-1, older age, and family history of DM were related to DM in acromegaly [5,28]. A study evaluating the French acromegaly population has suggested that age, BMI, and hypertension were predictors of DM presence, but not IGF-1 and GH [6]. IGF-1 level at the diagnosis time and the presence of hypertension were found to be associated with DM development in another study including Mexican patients with acromegaly [29]. Our study revealed that the FABP-4 is an independent predictor of DM.

That having a small size of samples in groups is a limitation of our study. However, the number of patients may be acceptable considering the rarity of acromegaly. We also included all patients newly diagnosed with acromegaly in our institute within the defined period to eliminate any bias. A point that needs to be clarified is that the obesity rate of control subjects is close to the rate of the patients with acromegaly. However, controls were selected randomly and we did not determine any relationship between obesity and FABP-4 levels.

In conclusion, the FABP-4 level was determined to be higher in the patients with acromegaly having DM and it may be a helpful predictor of acromegaly-associated DM.

### Table 3. Binary logistic regression analysis results showing the predictive values of the parameters for the presence of diabetes mellitus.

|       | B    | SE   | OR   | 95% CI      | p value |
|-------|------|------|------|-------------|---------|
| Age   | 0.186| 0.117| 0.111| 0.95–1.51   | 0.953   |
| Sex   | 0.079| 1.33 | 1.082| 0.1–14.7    | 0.953   |
| GH    | 0.102| 0.058| 1.107| 0.98–1.24   | 0.077   |
| IGF-1 | 0.005| 0.004| 1.005| 0.99–1.01   | 0.243   |
| FABP-4| 7.382| 3.11 | 38.96| 1.52–5.76   | 0.018   |

**Abbreviations:** SE: standard error, OR: odds ratio, CI: confidence interval, IGF-1: insulin-like growth factor-1, GH: growth hormone, FABP-4: fatty acid-binding protein 4.
Acknowledgments/disclaimers/conflict of interest
This research received no outside support. The authors have no financial interest with any organization. The authors have no conflicts of interest to declare. Authors thank to the members of cardiology department for performing echocardiography.

Informed consent
The Ethics Committee of our institute approved this study regarding the principles of the Helsinki Declaration (Clinical Research Ethics Committee University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Approval number: 71/08). Written informed consent was taken from all participants before being participated in the study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Contribution of authors
SH, PA, ES, DS, and EC contributed to the study conception and design. SH, PA, IU, DS, ES, BU, SMB, MC, and HD performed material preparation and data collection. SH performed the statistical analyses. SH wrote the first draft of the manuscript. EC and MO supervised the study. All authors commented on the manuscript. All authors read and approved the final manuscript.

References
1. Lavrentaki A, Paluzzi A, Wass JAH, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary 2017; 20 (1): 4–9. doi:10.1007/s11102-016-0754-x
2. Mercado M, Ramírez-Rentería C. Metabolic complications of acromegaly. Frontiers of Hormone Research 2018; 49: 20–28. doi:10.1159/000486001
3. Gözü HI, Öztürk D, Güleryüzü Y, Volkan Ö, Dündar C et al. Evaluation of cardiovascular parameters in acromegalic patients. Turkish Journal of Endocrinology and Metabolism 2007; 11: 1–6
4. Dreval A V, Trigolosova I V, Misnikova I V, Kovalyova YA, Tishenina RS et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocrine Connections 2014; 3 (2): 93–98. doi:10.1530/EC-14-0021
5. Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2014; 17 (1): 81–89. doi:10.1007/s11102-013-0471-7
6. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. European Journal of Endocrinology 2011; 164 (6): 877–884. doi:10.1530/EJE-10-1050
7. Ferreira F, Albani A, Ciresi A, Giordano C, Cannavo S. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Frontiers in Endocrinology 2018; 9: 358. doi:10.3389/fendo.2018.00358
8. Olarescu NC, Bollerstedt J. The impact of adipose tissue on insulin resistance in acromegaly. Trends in Endocrinology and Metabolism 2016; 27 (4): 226–237. doi:10.1016/j.tem.2016.02.005
9. Trojnar M, Patro-Małysza J, Kimber-Trojnar Z, Leszczyńska-Gorzelak B, Mosiewicz J. Associations between Fatty Acid-Binding Protein 4A proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells 2019; 8 (3): 227. doi:10.3390/cells8030227
10. Zhang Y, Zhang H-H, Lu J-H, Zheng S-Y, Long T et al. Changes in serum adipocyte fatty acid-binding protein in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnancy. Journal of Diabetes Investigation 2016; 7 (5): 797–804. doi:10.1111/jdi.12484
11. Li J-C, Wu D-A, Hou J-S, Suheq Y-M, Chen H-D et al. High serum adipocyte fatty acid binding protein is associated with metabolic syndrome in patients with type 2 diabetes. Journal of Diabetes Research 2016; 2016: 8380279. doi:10.1155/2016/8380279
12. Djoussé L, Gaziano JM. Plasma levels of FABP4, but not FABP3, are associated with increased risk of diabetes. Lipids 2012; 47 (8): 757–762. doi:10.1007/s11745-012-3689-7
13. Katznelson L, Laws ER, Melmed S, Melitch ME, Murad MH et al. Acromegaly: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism 2014; 99 (11): 3933–3951. doi:10.1210/jc.2014-2700
14. American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in Diabetes-2019. Diabetes Care 2019; 42 (Suppl 1): S13–28. doi:10.2337/dc19-S002
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (7): 412–419. doi:10.1007/bf00280883
16. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization Technical Report Series 2000; 894: i–xii, 1–253.

17. Lovic D, Narayan P, Pittaras A, Faselis C, Doumas M et al. Left ventricular hypertrophy in athletes and hypertensive patients. Journal of Clinical Hypertension (Greenwich). 2017; 19 (4): 413–417. doi:10.1111/jch.12977

18. Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 2011; 14 (3): 231–235. doi:10.1007/s11102-010-0284-x

19. Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009; 30 (2): 152–177. doi:10.1210/er.2008-0027

20. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clinical Endocrinology 2000; 52 (5): 549–555. doi:10.1046/j.1365-2265.2000.00986.x

21. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism--novel insights from genome-wide studies. FEBS Letters 2010; 584 (15): 3242–3249. doi:10.1016/j.febslet.2010.06.010

22. Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M. FABP4 attenuates PPARy and adipogenesis and is inversely correlated with PPARy in adipose tissues. Diabetes 2014; 63 (3): 900–911. doi:10.2337/db13-0436

23. Patro-Małysza J, Trojan M, Kimber-Trojnar Z, Mierzyński R, Bartosiewicz J, et al. FABP4 in gestational diabetes association between mothers and offspring. Journal of Clinical Medicine 2019; 8 (3): 285. doi:10.3390/jcm8030285

24. Xu A, Wang Y, Xu JY, Stejskal D, Tam S et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clinical Chemistry 2006; 52 (3): 405–413. doi:10.1373/clinchem.2005.062463

25. Holm S, Ueland T, Dahl TB, Michelsen AE, Skjelland M et al. Fatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. PloS One 2011; 6 (12): e28785. doi:10.1371/journal.pone.0028785

26. Tso AWK, Xu A, Sham PC, Wat NMS, Wang Y et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007; 30 (10): 2667–2672. doi:10.2337/dc07-0413

27. Zhang Y, Yu H, Gao P, Chen J, Yu C et al. The effect of growth hormone on lipid accumulation or maturation in adipocytes. Cellular Physiology and Biochemistry 2016; 39 (6): 2135–2148. doi:10.1159/000447909

28. Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. The Journal of Clinical Endocrinology and Metabolism 2005; 90 (4): 1972–1978. doi:10.1210/jc.2004-2009

29. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Díaz AM, García-Dominguez A et al. The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. The Journal of Clinical Endocrinology and Metabolism 2016; 101 (11): 3997–4004. doi:10.1210/jc.2016-1937